Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GXO Logistics Inc (GXO) vs Eli Lilly And Co (LLY) Price & Performance

GXO Logistics IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

GXO Logistics Inc vs Eli Lilly And Co — how do they compare? GXO Logistics Inc trades at $54.2 (market cap $6.02B), while Eli Lilly And Co trades at $1,170.97 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 171.1× GXO Logistics Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.

GXOLLY
Market Cap
$6.02B$1.03T
Sector
IndustrialsHealth
52-Week High
$65.59$1.24K
52-Week Low
$45.52$625.65
Enterprise Value
$11.18B$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GXO Logistics Inc

GXO Logistics is trading at $53.36, up 7.43% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamental performance with three consecutive quarterly earnings beats and 10.8% revenue growth in Q1 2026. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $66.60 consensus price target representing 25% upside potential. Recent business developments include multiple partnership renewals and expansion into strategic verticals like aerospace and defense.

GXO presents a compelling investment opportunity with strong earnings momentum and institutional support, though investors should monitor competitive pressures from Amazon's logistics expansion and the company's transition toward higher-margin verticals. The stock's current valuation at 46.69x P/E appears elevated relative to modest net margins, requiring continued execution on growth initiatives to justify premium multiples.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.

Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GXO Logistics Inc

GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.

Read more on GXO

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY